| 摘要: |
| 目的 通过对新型冠状病毒(2019 novel coronavirus,2019-nCoV)mRNA疫苗(简称新冠mRNA疫苗)免疫小鼠后产生的中和抗体进行检测,探索中和抗体检测法应用于mRNA疫苗体内效力评价的可行性。方法 采用6~8周BALB/c小鼠进行后肢肌肉免疫,检测不同免疫剂量和不同免疫程序的中和抗体滴度。并对8家企业生产的新冠mRNA疫苗免疫的小鼠血清进行中和抗体和IgG抗体检测。结果 2 µg、5 µg、10 µg不同剂量mRNA疫苗按照不同免疫程序免疫小鼠后中和抗体检测结果显示,抗体阳转率均为100%,中和抗体反应有明显的剂量-效应关系。2针间隔14 d加强免疫组抗体滴度显著高于间隔7d加强免疫组及一针组(F=57.13, P<0.001)。2 µg剂量间隔7 d加强免疫和间隔14 d加强免疫产生的中和抗体几何平均滴度(geometric mean titer,GMT)分别为218和468,差异有统计学意义(t=3.40, P=0.003);5 µg剂量间隔7 d加强免疫和间隔14 d加强免疫产生的中和抗体GMT分别为499和1 436,差异有统计学意义(t=3.62,P=0.002);10 µg剂量间隔7 d加强免疫和间隔14 d加强免疫产生的中和抗体GMT分别为608和1 909,差异有统计学意义(t=3.23,P=0.005)。国内8家企业生产的新冠mRNA疫苗免疫小鼠后均可产生高滴度的IgG抗体(104.5~107.5)和中和抗体(102.6~104.8),效力测定结果均符合企业质量标准。各企业生产的mRNA疫苗的中和抗体滴度结果差异有统计学意义(F=70.03,P<0.001)。结论 小鼠免疫后中和抗体检测可用于mRNA疫苗的体内效力评价。 |
| 关键词: 新型冠状病毒 mRNA疫苗 中和抗体 IgG抗体 效力 |
| DOI:10.13506/j.cnki.jpr.2023.11.009 |
| 基金项目:国家重点研发计划(No.2021YFC2302404) |
|
出版日期:2023-11-25
|
|
| Study on the potency of mRNA COVID-19 vaccine in vivo using neutralizing antibody assay |
| WU Xiaohong,ZHAO Danhua,SUO Yue,PENG Qinhua,WANG Hongyu,LIU Xinyu,LI Yuhua |
| (NMPA Key Laboratory for Quality Control and Evaluation of Biological Products, Division of Arbovirus Vaccine, National Institutes for Food and Drug Control, Beijing 102629, China) |
| Abstract: |
| Objective To evaluate the potency of mRNA COVID-19 vaccine in vivo by neutralizing antibody assay after mice immunization, and establish a method to evaluate the efficacy of the vaccine.Methods BALB/c mice at 6~8 weeks were immunized with mRNA COVID-19 vaccine and the neutralizing antibody titers of different immune dosage and different vaccination schedules were detected. The variant vaccines produced by different manufactures were immunized at intervals of 7 d or 14 d, and Serum samples was collected at 7 d after the second dose of immunization. 2019 novel coronavirus (2019-nCoV) neutralizing antibody titer and IgG antibody titer were detected by pseudo virus neutralization test and enzyme linked immunosorbent assay separately. Results The results of neutralizing antibody at different immune dosage of 2 µg, 5 µg, 10 µg mRNA vaccine showed that the seropositive rate of antibody in mice was 100% and the neutralizing antibody reaction had an obvious dose-effect correlation. The neutralization antibody titer of the 14-day interval group was significantly higher than that of the 7-day interval group and one dose group (F=57.13, P<0.001). The geometric mean titers (GMT) of neutralizing antibody induced by 2µg dosage interval of 7-day and 14-day were 218 and 468,respectively, with significant difference (t=3.40, P=0.003);The GMT of neutralizing antibody induced by 5 µg dosage interval of 7-day and 14-day were 499 and 1 436,respectively, with significant difference (t=3.62, P=0.002); The GMT of neutralizing antibodies induced by 10 µg dosage interval of 7-day and 14-day were 608 and 1 909 respectively, with significant difference (t=3.23, P=0.005). High levels of IgG antibody(104.5~107.5) and neutralizing antibody (102.6~104.8)could be detected after immunizing mice with the COVID-19 mRNA vaccine, potency of the vaccines were all met with the requirements with good lot consistence, there were significant difference in the antibody titers among the various vaccine produced by different manufacturers (F=70.03, P<0.001).Conclusion The neutralizing antibody test of the mice after immunization can be used to evaluate the potency of COID-19 mRNA vaccine in vivo. |
| Key words: 2019 novel coronavirus mRNA vaccine Neutralizing antibody IgG antibody Potency |